Prevention Innovation Program III (PIP) (R01)

Post Date

March 29th 2016

Application Due Date

August 3rd 2016

Funding Opportunity Number

RFA-AI-16-025

CFDA Number(s)

93.855
93.856

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $1800000

• Award Range:

  $None - $400000

Grant Description

The Prevention Innovation Program III (PIP) encourages research applications in Non-vaccine Biomedical Prevention (nBP) research. The PIP is intended to support high-risk/innovative research and development efforts to establish and maintain a sustainable pipeline for the prevention of HIV acquisition/transmission. The PIP will support: 1) discovery and development of novel and under-explored nBP candidates/strategies, 2) discovery and development of nBP drug delivery systems (DDS), 3) studies of the impact of nBP prevention products and DDS on genital and gastrointestinal (GI) mucosa function, 4) development of emerging technologies to support and facilitate nBP prevention product and DDS discovery and development, 5) development of age appropriate formulation strategies (AFS), and 6) development of Multipurpose Prevention Technologies (MPT) for prevention of HIV acquisition/transmission.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-16-025.html